Pregabalin Versus Placebo as an Add on for Complex Regional Pain Syndrome (CPRS) of the Upper Limb Managed by Stellate Ganglion Block (The PREGA Study) (PREGA)
Pregabalin vs. Placebo as an Add on for Complex Regional Pain Syndrome of the Upper Limb Managed by Stellate Ganglion Block
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 2X2
- Hamilton General Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients diagnosed with CRPS Type I as per the IASP (International Association for the Study of Pain) criteria which states presence of an initiating noxious event, or cause for immobilization
- Evidence at some point of swelling, color change, hot/cold/sweaty sensation and no other condition which can account for the pain and dysfunction of the upper limb
- Men or women between ages 18-65 year old
- Women should not be pregnant or breast feeding
- No change in treatment for 4 weeks prior to recruitment
- Pain scores of 4/10 on a verbal analogue scale
Exclusion Criteria:
- Patients with a neurologic disorder unrelated to CRPS
- Patients who are already on pregabalin
- Patients with renal impairment whose creatinine clearance is less than 60 ml/min
- Patients with congestive heart failure who are also diabetic and taking thiazolidinedione medication like rivoglitazone
- Unstable psychiatric history
- Patients with another problem with equal or worse pain
- Unstable medical condition
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1
Pregabalin group is made up of 20 patients.
Patients will receive 150mg/day in two divided does.
The patients will be assessed weekly and the dose can be increased to 300mg/day, if the patient does not report any decrease in pain.
The following week the dose may be increased to 600mg/day if once again the patient reports no decrease in pain.
This is also the maximum permissible does that will be given to the patient.
If patient reports any side effects then the dose can be decreased once.
The time period of 2 to 5 weeks will be the dose adjustment period.
After which the drug maintenance period extends from week 5 to 12.
All doses will be given in two divided doses/day.
|
Dose of 150mg/day divided in two doses.
Increased to 300mg/day then to 600mg/day, always divided in two doses for the day.
Other Names:
|
|
Placebo Comparator: 2
Ten patients will be be in the placebo group.
|
Sugar pill
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Pain relief assessed by an observer blinded to group allocation with daily pain scores and assessed weekly.
Time Frame: Three months
|
Three months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Functional disability assessed by an observer blinded to group allocation. Patient rated wrist and hand evaluation form.
Time Frame: Three months
|
Three months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Norman Buckley, MD, Hamilton Health Sciences Corporation
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neurologic Manifestations
- Nervous System Diseases
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Autonomic Nervous System Diseases
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Pain
- Complex Regional Pain Syndromes
- Amino Acids, Peptides, and Proteins
- Organic Chemicals
- Acids, Acyclic
- Carboxylic Acids
- Amino Acids
- gamma-Aminobutyric Acid
- Aminobutyrates
- Butyrates
- Pregabalin
Other Study ID Numbers
Other Study ID Numbers
- 07-181
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.